Iridex to Report Second Quarter 2025 Financial Results on August 12, 2025
Rhea-AI Summary
Iridex (Nasdaq: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, has scheduled its second quarter 2025 financial results release for August 12, 2025 after market close.
The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join via phone at +1-888-596-4144 using passcode 2197032, or access the webcast through Iridex's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – IRIX
In the trading session that priced this news, IRIX declined 0.71%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.8% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the second quarter 2025 and provide a business update after the close of trading on Tuesday, August 12, 2025.
The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing passcode: 2197032 followed by pressing #. A live and recorded webcast will be available on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com
